Sugi Predict

Sugi Predict / Compounds / SCHEMBL2633152

SCHEMBL2633152

SCHEMBL2633152

COc1cc2ccccc2c(C)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGES O14684 1/20 0.49
▸ ALOX5 P09917 1/20 0.49
▸ NQO1 P15559 1/20 0.48
▸ KDM4E B2RXH2 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ MAOA P21397 2/20 0.46
▸ MAPT P10636 3/20 0.46
▸ POLB P06746 3/20 0.45
▸ ABL1 P00519 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ APEX1 P27695 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ CDK5 Q00535 1/20 0.45
▸ MCL1 Q07820 1/20 0.45
▸ RIN1 Q13671 1/20 0.45
▸ CDK5R1 Q15078 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14264196 0.88 NQO1 (0.52) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL2889415 0.84 MAOA (0.58) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL20562355 0.83 NQO1 (0.41) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL12130824 0.82 ALDH1A1 (0.48) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL27423013 0.82 MAOA (0.56) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL25019932 0.79 NQO1 (0.47) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL2328658 0.79 PTGES (0.48) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL20562674 0.79 NQO1 (0.47) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL11658556 0.79 ALDH1A1 (0.45) PTGESALOX5NQO1KDM4ESMN1; SMN2
SCHEMBL7301542 0.79 PTGES (0.51) PTGESALOX5NQO1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110003616-A Composition epoxy resin and its solidfied material 日铁化学材料株式会社 2019-07-12 — — CN disclosed
CN-107083027-A Oxazines resin combination and its manufacture method, prepreg, plywood and hardening thing 新日铁住金化学株式会社 2017-08-22 — — CN disclosed
CN-106467653-A Flame-retardant epoxy resin omposition, prepreg, insulating trip, adhesive sheet, plywood, encapsulant, cast material and solidfied material 新日铁住金化学株式会社 2017-03-01 — — CN disclosed
EP-2185507-B1 FUNGICIDE N-6-MEMBERED FUSED (HETERO)ARYL-METHYLENE-N-CYCLOALKYL CARBOXAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2012-04-25 — — EP disclosed
CN-101652356-A Stable anhydrous crystalline docetaxel and method for the preparation thereof HANMI PHARM IND CO LTD KR 2010-02-17 — — CN disclosed
EP-1361225-B1 COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS SANKYO CO (JP) 2007-11-07 — — EP disclosed
US-7122666-B2 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-10-17 — — US disclosed
US-7091352-B2 Compounds substituted with bicyclic amino groups SANKYO COMPANY, LIMITED (JP) 2006-08-15 — — US disclosed
US-20060128756-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2006-06-15 — — US disclosed
EP-1377577-B1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES SANKYO CO (JP) 2006-06-14 — — EP disclosed
EP-1070711-B1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO CO (JP) 2004-04-14 — — EP disclosed
US-20040054173-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses SANKYO COMPANY, LIMITED (JP) 2004-03-18 — — US disclosed
EP-1377577-A1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES Sankyo Company Limited (JP) 2004-01-07 — — EP disclosed
EP-1361225-A1 COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS Sankyo Company, Limited (JP) 2003-11-12 — — EP disclosed
EP-1352906-A1 COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY Sankyo Company, Limited (JP) 2003-10-15 — — EP disclosed
EP-1243589-A1 Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses Sankyo Company Limited (JP) 2002-09-25 — — EP disclosed
WO-2002057264-A1 PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES SANKYO COMPANY LIMITED (JP) 2002-07-25 — — WO disclosed
EP-1070711-A2 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses Sankyo Company Limited (JP) 2001-01-24 — — EP disclosed
US-4327022-A Heterocyclic alkyl naphthols STERLING DRUG INC. (US) 1982-04-27 — — US disclosed
US-4169108-A 5(OR 6)-[(Substituted-amino)alkyl]-2,3-naphthalenediols STERLING DRUG INC. (US) 1979-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128756-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, IL1A, IL1B PTGES 193/4885ALOX5 427/4885NQO1 332/4885
US-20040054173-A1 Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses IL2, IL1B, IL1A PTGES 140/4885ALOX5 126/4885NQO1 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.